Vivoryon Therapeutics N.V. · EURONEXT:VVY
Vivoryon Therapeutics — Probiodrug — FY2015 Earnings Presentation
28 slides from Vivoryon Therapeutics's earnings presentation, Mar 15, 2016
Slide 1: The 2015 financial year – Full year results
The 2015 financial year Full year results Halle (Saale), 15 March 2016 Konrad Glund Hendrik Liebers Inge Lues Frank Weber CEO CFO CDO CMO
Slide 2: Important notice and disclaimer
Important notice and disclaimer This Presentation has been prepared and issued by Probiodrug AG (the “Company”) and has not been independently verified by any third party. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any proj
Slide 3: Content
Content 1. Corporate introduction 2. Results 2015 3. Outlook 4. Q & A 3
Slide 4: Investment highlights
Investment highlights Alzheimer’s Disease (“AD”) is the most common form of dementia, a 1 Alzheimer’s Disease: major burden, no cure devastating neurological disease affecting 46 million people world-wide* No cure or long-term beneficial treatment available No new drugs approved since 2007**
Slide 5: Longstanding track-record and renowned investor base
Longstanding track-record and renowned investor base Brief history Major investors (> 3%) 1997: Foundation, pioneered a new class of anti-diabetics (gliptins) – partnerships with Merck & Co, Ferring and Novartis 2004: Sold diabetes franchise to OSI Pharmaceuticals – proceeds partially returned t
Slide 6: Experienced management team
Experienced management team Management team Biography Konrad Glund, Co-founder of Probiodrug, CEO since 2006 PhD CEO Led development of DP 4 inhibitors, transactions with Merck, Novartis, OSI and Ferring Co-founder COO & VP business development OSI (Prosidion) in 2004-2006 Chairman of the >
Slide 7: Alzheimer's Disease: growing burden, no cure
Alzheimer's Disease: growing burden, no cure Worldwide dementia population will triple Alzheimer's Disease introduction in the next 30 years* Leading cause of dementia, ultimately CAGR leading to death +3% 132 Large burden on families 46 Growing cost for society Available treatments marginal
Slide 8: Original Abeta approach
Original Abeta approach Probiodrug targets toxic structures in Alzheimer's Disease Considerations* Most new drug treatments Most new drugs have focused on Abeta formation or Abeta/plaque clearance have targeted Abeta or plaques Therapies have focused on: 1. Reduction of Abeta formation 2. Cleara
Slide 9: Probiodrug's differentiated approach
Probiodrug’s differentiated approach Probiodrug targets toxic structures in Alzheimer's Disease Considerations* Probiodrug and others Most new drugs have focused on Abeta formation or Abeta/plaque clearance have progressed insights on Abeta and its role in AD Abeta has a physiological function
Slide 10: pGlu-Abeta - N-modified Abeta
pGlu-Abeta - N-modified Abeta Jawhar, S., Wirths, O., Bayer, T.A. JBC 286, 45, 2011 10
Slide 11: Focused proprietary pipeline
Focused proprietary pipeline Pre- Product Phase 1 Phase 2 clinical PQ912 Small molecule QC inhibitor Trial ongoing PBD-C06 pGlu-Abeta specific monoclonal antibody PQ1565 Small molecule QC inhibitor Clinical proof of concept 11
Slide 12: The Probiodrug Share
The Probiodrug Share KEY INFORMATION SHAREHOLDER (> 3%) ISIN: DE0007921835 WKN: 792183 Ticker Symbol: PBD Type of shares: Bearer shares Number of shares: 7,442,487 Stock exchange: Euronext Amsterdam Liquidity Provider: Kempen & Co. Listing Agent: Kempen & Co. First trading day: 27
Slide 13: Content
Content 1. Corporate introduction 2. Results 2015 3. Outlook 4. Q & A 13
Slide 14: Highlights 2015
Highlights 2015 2015 Phase 2a study of novel treatment for Alzheimer’s disease, the SAPHIR trial, initiated Phase 1 PQ912 data, a first in class Glutaminyl Cyclase (QC) inhibitor for the treatment of AD, published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions Manuf
Slide 15: Highlights 2015 – cont.
Highlights 2015 – cont. 2015 Several high-caliber academic collaborations continued or initiated, eg. with the Brigham and Women’s Hospital, affiliated with Harvard Medical School and with University of Leipzig, Paul Flechsig Institute for Brain Research Winner of the European Mediscience Award
Slide 16: Key financial figures (according to IFRS)
Key financial figures (according to IFRS) In EUR k 2015 2014 Earnings, Financial and Net Assets Position Revenues 0 0 Operating loss -13,393 -11,267 Net loss for the period -13,505 -11,437 Equity (end of the year) 16,133 15,971 Equity ratio (end of the year) (in %) 73.8 74.4 Balance sheet total (end
Slide 17: Details of the Financial Results (according to IFRS)
Details of the Financial Results (according to IFRS) Net loss net loss Net loss in line with expectations Operating loss primarily driven by R&D expenses Increase in operating expenses reflects operating loss EUR 13,393 k primarily investments in PQ912 financial loss EUR 112 k Financial loss
Slide 18: Operational Review (1)
Operational Review (1) Pipeline Update PQ912 First QC-inhibitor being tested in humans In preceding Phase 1 study with healthy young and elderly volunteers shown to be safe, well tolerated and revealed high QC-inhibition SAPHIR is a randomized, double-blind multi-center study Patient enrolme
Slide 19: Operational Review (2)
Operational Review (2) PBD-C06 Monoclonal antibody targeting pGlu-Abeta, while leaving non-toxic forms of Abeta untouched Currently in preclinical stage Successfully humanized and de-immunized For the first time for an anti-pGlu-Abeta-antibody approach PBD-C06 has not only shown the ability
Slide 20: Operational Review (3)
Operational Review (3) Publications/ Presentations March 2015: additional data on Glutaminyl Cyclases (QCs) in its relation to Alzheimer’s disease published in Acta Neuropathologica 2015 Apr, 129(4), Pages 565-83 Further evidence of strong correlation between QCs and AD pathology in human brain
Slide 21: Operational Review (4)
Operational Review (4) Publications October 2015: Oral presentation “Preclinical in vivo Effects of an anti-PyroGlu-3 Abeta Antibody” presented data on its specific anti pGlu-Abeta monoclonal antibody at Neuroscience 2015, the 45th annual meeting of the Society for Neuroscience (SfN) in Chicago, U
Slide 22: Operational Review (5)
Operational Review (5) IP In 2015, IP position further strengthened by important patent applications being granted: Patent no. US 9,156,907 and JP 5,828,762, covering method as well as composition of matter claims for Probiodrug’s antibody program targeting pGlu-Abeta, were granted in the US and
Slide 23: Corporate Review
Corporate Review Execution of a private placement on Nov, 5, 2015 Increase of share capital from EUR 6,765,898 to EUR 7,442,487, issuing 676,589 new shares Representing appr. 10% of the issued share capital at the time of the placement Gross proceeds of EUR 13.5 million Order book well cover
Slide 24: Content
Content 1. Corporate introduction 2. Results 2015 3. Outlook 4. Q & A 24
Slide 25: Outlook
Outlook Mid-term focus of Probiodrug’s business activities can be summarised as follows: Continue the clinical development of PQ912 in particular generate initial patient study data and start long-term treatment Completion of the production development of PBD-C06 and conduction of regulatory tox
Slide 26: Anticipated news flow (selection)
Anticipated news flow (selection) 2014 2015 2016 First patient enrolled in PQ912 Phase 2a ✔ ✔ “SAPHIR” study at leading Alzheimer Center in PQ912 results of long term tox studies Amsterdam PQ912 POP* combination therapy with Additional data on Glutaminyl Cyclases (QCs) ✔ in AD published in A
Slide 27: Financial Calendar
Financial Calendar 12 May 2016 Interim Management Statement Q1 2016 19 May 2016 Annual General Meeting of Shareholders in Berlin 30 August 2016 Interim Report, half year results 2016 10 November 2016 Interim Management Statement Q3 2016 27
Slide 28: Content
Content 1. Corporate introduction 2. Results 2015 3. Outlook 4. Q & A 28